8-K: Modular Medical Secures $350K CEO-Backed Credit Line

Modular Medical, Inc. has secured a $350,000 revolving credit facility from its CEO, James E. Besser, due March 25, 2026, at a 12% interest rate.

Summary

• Modular Medical, Inc. (the Company) entered into a secured promissory note on February 23, 2026.
• The note provides a $350,000 revolving credit facility.
• The lender is James E. Besser, the Company's chief executive officer (via Manchester Explorer, L.P.).
• All amounts drawn are due and payable by March 25, 2026 (the Maturity Date).
• Interest is payable at a rate of 12% on each draw down, fully earned upon advance.
• The loan is secured by all assets and intellectual property of the Company.
• As of February 24, 2026, no borrowings have been made under the note.
• The principal and interest are also due earlier if the Company receives over $2,000,000 from equity financings or other equity issuances before the Maturity Date.
• Individual draw amounts must be at least $50,000 and not exceed the remaining facility amount.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it highlights immediate liquidity needs, high cost of capital, and reliance on related-party financing, which typically signals underlying financial challenges for a publicly traded company.

Positives

• Secured immediate access to $350,000 in revolving credit, providing short-term liquidity.
• The CEO's willingness to provide financing demonstrates a commitment to the Company's operations.

Negatives

• The credit facility has a very short maturity date of March 25, 2026, indicating immediate and pressing financial needs.
• A 12% interest rate for a short-term loan, even from a related party, is relatively high, suggesting a high-risk profile or limited alternative financing options.
• The loan is secured by all of the Company's assets and intellectual property, which could limit future financing options or increase risk for other creditors.
• The transaction is a related-party dealing, which can raise corporate governance concerns regarding potential conflicts of interest.

Risks

• **Liquidity Risk:** The extremely short maturity date (approximately one month) creates significant liquidity risk, as the Company must repay the full amount plus interest by March 25, 2026, or secure substantial equity financing.
• **Default Risk:** Failure to repay the loan by the Maturity Date or upon an Event of Default (e.g., failure to make payments, material breach of note provisions, bankruptcy) could lead to acceleration of the debt and potential enforcement against all Company assets.
• **Financing Risk:** The Company's reliance on a related-party loan, especially with a high interest rate and broad collateral, suggests challenges in securing traditional third-party financing, indicating potential underlying financial weakness.
• **Dilution Risk:** The acceleration clause tied to receiving over $2,000,000 from equity financings implies a potential need for significant future equity raises, which could lead to substantial shareholder dilution.
• **Corporate Governance Risk:** Related-party transactions, particularly those involving the CEO as a lender and secured by all company assets, can present conflicts of interest and scrutiny regarding fairness to minority shareholders.

Future Outlook

The Company anticipates potentially raising over $2,000,000 through equity financings or other issuances of equity securities prior to the loan's maturity date, which would trigger an accelerated repayment of the credit facility.

Management Comments

• "Modular Medical, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 24, 2026 /s/ James E. Besser James Besser Chief Executive Officer"
• "IN WITNESS WHEREOF, the parties have caused this Note to be executed on and as of as of the date first written above. Borrower By: /s/ Paul DiPerna Name: Paul DiPerna Title: President Date: February 23, 2026"

Industry Context

StockSavvy.ai notes that securing a short-term, high-interest, fully secured loan from a CEO is often a characteristic of smaller, early-stage, or financially constrained companies, particularly in capital-intensive sectors like medical devices. This type of financing can indicate challenges in accessing more conventional debt or equity markets, suggesting a higher perceived risk by external investors.

Comparison to Industry Standards

• A 12% interest rate for a one-month revolving credit facility, secured by all company assets and intellectual property, is significantly higher than typical corporate credit lines offered by commercial banks to established companies (which might range from prime rate + 1-3% for unsecured, or lower for secured).
• For example, a well-capitalized medical device company like Medtronic or Abbott Laboratories would secure much larger facilities at substantially lower rates and with less restrictive collateral requirements.
• This arrangement suggests Modular Medical, Inc. faces a higher cost of capital and potentially limited financing alternatives, placing it outside the standard financing practices for financially robust public companies.

Corporate Governance

Related Party Transactions

• Modular Medical, Inc. entered into a $350,000 secured revolving credit facility with James E. Besser, the Company's Chief Executive Officer (identified as the Lender in the 8-K, and Manchester Explorer, L.P. in the promissory note).

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity raises (implied by the acceleration clause) and increased risk due to all company assets being pledged as collateral for a short-term, high-interest loan. The related-party nature of the loan may also raise governance concerns.
• **Creditors:** The new loan is secured by all assets and intellectual property, potentially subordinating other unsecured creditors or limiting the Company's ability to secure additional debt financing.
• **Employees:** The immediate need for short-term financing and the high cost of capital could signal financial instability, potentially impacting employee morale or future job security.

Next Steps

• Repayment of the $350,000 credit facility plus 12% interest by March 25, 2026.
• Potential pursuit of equity financings exceeding $2,000,000, which would accelerate the loan repayment.

Key Dates

Recommendation

The filing reveals a company in immediate need of short-term capital, evidenced by a very brief maturity period (one month) and a high 12% interest rate for a secured revolving credit facility. The fact that this loan is provided by the CEO and secured by all company assets and intellectual property strongly suggests limited access to conventional financing and significant financial distress. This situation increases the risk of default, potential asset liquidation, and substantial shareholder dilution from any necessary future equity raises. For a publicly traded company, these are highly negative indicators that warrant a strong sell recommendation.

Keywords

Modular Medical, MODD, credit facility, promissory note, revolving credit, related party transaction, CEO loan, short-term debt, secured loan, equity financing, corporate governance, liquidity, financial risk